Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart flutters may weaken lungs and muscles, new study suggests

NCT ID NCT07396597

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study looks at how premature ventricular complexes (extra heartbeats) impact breathing, muscle strength, physical activity, and quality of life. Researchers will measure lung function, cough strength, handgrip strength, and daily activity in 52 adults with this condition. The goal is to better understand the full-body effects of PVCs, not to test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adults including individuals diagnosed with symptomatic premature ventricular complexes and healthy control participants. Participants will be recruited from patients presenting to the Cardiology Department of Buca Seyfi Demirsoy Training and Research Hospital and volunteers without premature ventricular complexes.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs): * Aged between 18 and 80 years * Presence of symptomatic premature ventricular complexes resistant to ≥1 antiarrhythmic medication (including β-blockers and calcium channel blockers) * Premature ventricular complex burden ≥10% * Ventricular arrhythmias originating from any focus within the right or left ventricle * Physically able to participate in all study assessments * Willingness to participate in the study by providing written informed consent Inclusion Criteria for Control Group Participants: * Aged between 18 and 80 years * Healthy individuals * Willingness to participate in the study * Physically able to participate in all study assessments Exclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs): * Left ventricular ejection fraction (LVEF) \<45% unless PVC-induced cardiomyopathy is documented (defined as a \>15% improvement in LVEF following reduction of PVC burden through pharmacological therapy or ablation) * Progressive decline in LVEF within the last 4 months, regardless of etiology * Severe heart failure classified as New York Heart Association (NYHA) Class ≥III * Ventricular arrhythmias attributed to underlying structural heart disease, known myocardial scar, or myocarditis * Change in the dosage of antiarrhythmic medications (including β-blockers and calcium channel blockers) within 2 months prior to enrollment * Failed catheter ablation within 3 months prior to enrollment * Known thyroid disorders or individuals undergoing renal dialysis * Life expectancy \<12 months * Presence of angina pectoris * Diagnosis of chronic obstructive pulmonary disease (COPD) or asthma * Resting heart rate \>120 beats/min * Resting systolic blood pressure ≥180 mmHg * Resting diastolic blood pressure ≥100 mmHg * Resting peripheral oxygen saturation ≤90% Exclusion Criteria for Control Group Participants: * Presence of premature ventricular complexes * Presence of any acute or chronic medical condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature ventricular complexes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cough Ventricular Premature Complexes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Izmir Democracy University

    Izmir, 35140, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.